根据合作协议，双方将发挥互补优势，加快推进创新药物的全球研发工作。信达生物依托自身成熟的抗 体技术平台及高效的临床能力，将主导相关项目从药物发现至中国临床概念验证（二期临床试验完成） 的研发工作。根据协议，礼来获得相关项目在大中华区以外的全球独家开发与商业化许可，信达生物保 留相关项目在大中华区的全部权利。 根据协议条款，信达生物将获得3.5亿美元首付款；在达成后续特定里程碑事件后，信达生物还有资格 获得总额最高约85亿美元的研发、监管及商业化里程碑付款。此外，信达生物有权就各产品在大中华区 以外的净销售额获得梯度的销售分成。 近日，信达生物制药集团宣布与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研 发。本次协议为双方第七次合作，进一步深化了双方长期且富有成效的合作伙伴关系，携手为全球患者 带来创新药物。 ...

Core Insights - Jefferies published an in-depth report focusing on the investment prospects of Roivant Sciences (ROIV.US), highlighting three key catalysts and valuation logic that could significantly impact the company's stock price by 2026 [1] Group 1: Key Catalysts - The first catalyst involves a patent lawsuit related to LNP technology with Moderna (MRNA.US) and Pfizer (PFE.US), with a trial set to begin on March 9, 2026. Conservative estimates suggest Roivant could receive $2-4.5 billion in damages based on a 5% royalty from total COVID-19 vaccine revenues of $60-130 billion [1] - The second catalyst is the Phase II clinical trial data for Pulmovant's PH-ILD treatment, which could lead to a Phase III trial if the data shows a reduction in pulmonary vascular resistance (PVR) of over 20%. The Phase III trial is expected to start in the first half of 2027, with results anticipated in 2030 [2] - The third catalyst is the Phase III trial data for Priovant's brepo drug, which has been moved up to the second half of 2026. If brepo captures 30-50% of the market for non-infectious uveitis (NIU) patients, peak sales could reach $1.5-3 billion [2] Group 2: Valuation Analysis - Jefferies utilized a sum-of-the-parts (SOTP) valuation method, estimating the expected compensation from the LNP lawsuit at $2.5-3 billion, with Roivant's share being $1.5-2 billion. The market value of the IMVT subsidiary is estimated at $5.4 billion, adjusted to $5.1 billion after accounting for cash [3] - The brepo drug is valued at $1.75 billion in peak sales, with a 5x price-to-earnings ratio and a 95% success rate, leading to a valuation of $6.25 billion for Roivant's stake [3] - Overall, the valuation framework indicates a clear picture, with current cash of $4.4 billion and projected cash of $3.7 billion, supporting a "buy" rating with a target price of $24, representing a 10.95% upside from the latest closing price of $21.63 [3]

Core Viewpoint - The company reported a revenue of 2.717 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 15.90% [2] - The EBITDA reached 860 million yuan, showing a year-on-year increase of 20.15%, although net profit did not grow at the same rate due to depreciation and amortization factors [2] Group 1 - The company currently has eight listed drugs, and revenue is expected to improve as drug promotion strategies are implemented [2] - The company is actively monitoring advancements in new drug development and plans to align its growth strategy accordingly [2]

Core Viewpoint - The company maintains rapid revenue growth, with domestic demand gradually recovering and new products developed for drug development processes opening up demand space, sustaining a buy rating [1] Investment Highlights - The company maintains a "buy" rating, adjusting the EPS forecast for 2025-2027 to 1.14/1.52/2.10 yuan (previously 0.94/1.19/1.51 yuan), assigning a 60X PE valuation for 2025, which reflects a certain discount compared to comparable companies due to stable operations and a robust growth outlook, with a target price of 68.12 yuan [2] - In the first half of 2025, the company achieved revenue of 387 million yuan (+29.38%) and a net profit attributable to shareholders of 83.8 million yuan (+47.81%), with a non-recurring net profit of 84.13 million yuan (+45.82%). In Q2 alone, revenue reached 201 million yuan (+30.95%) and net profit was 43.22 million yuan (+66.10%) [2] - Domestic revenue was 123 million yuan, a year-on-year increase of 36.65%, indicating a rapid recovery in domestic business, while overseas revenue was 258 million yuan, up 22.94%, maintaining competitive advantages [2] Profitability and Cost Control - In the first half of 2025, the company's gross margin was 90.14%, a decrease of 1.32 percentage points, while the net margin increased by 3.59 percentage points to 21.53% [3] - The company effectively controlled overall expense ratios, with sales/management/R&D/financial expense ratios at 29.69%/15.36%/23.26%/-7.20%, showing year-on-year changes of -2.60/-0.70/-2.87/-1.77 percentage points [3] R&D Investment - The company continues to increase R&D investment, expanding its R&D team to 279 personnel, with over 5,000 products sold and applied. It maintains competitiveness in recombinant proteins while developing new products for CGT and ADC drugs to adapt to new drug development rhythms [3] - In the CGT field, the company has successfully developed nearly 50 high-quality GMP-grade products, including cytokines and antibodies for cell activation; in the ADC field, it offers a range of high-quality products, including various target proteins and enzymes for linker cleavage [3]

Core Viewpoint - 康方生物科技 achieved significant milestones in 2024, including a 25% year-on-year increase in new drug sales revenue, reaching 2 billion yuan, and successfully including two core dual antibodies in the national medical insurance catalog, marking a strategic goal in domestic new drug commercialization [2][3] Commercialization Progress - The company’s dual antibodies, Cardunili (PD-1/CTLA-4) and Ivorosi (PD-1/VEGF), gained entry as star products in the national medical insurance negotiations, indicating a shift from an outpatient market focus to an inpatient market core [3][4] - To support market expansion post-insurance implementation, 康方生物 initiated a commercialization system upgrade, expanding its professional marketing team and enhancing hospital access and academic promotion capabilities [3][4] New Drug Development - 康方生物 received approvals for three new drugs and two new indications during the reporting period, with over 20 ongoing phase III clinical studies [2][5] - The international market expansion of Ivorosi is a focal point, with its international partner, Summit, advancing three international multi-center phase III clinical developments [5][6] Clinical Research and Global Strategy - The HARMONi study for Ivorosi is expected to release phase III data in mid-2025, which could lead to new drug application submissions in the US and Europe if results are positive [6] - The company is conducting a series of clinical therapy explorations covering over 40 indications, establishing a competitive barrier in the field of tumor immunotherapy [6][7] Company Achievements - 康方生物's founder and CEO highlighted the company's historical achievements in drug innovation and the approval of globally competitive products, enhancing its position in the international biopharmaceutical innovation landscape [7]